• Please log in or register to access this feature.

Original Article

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney †

A randomized, double-blind, placebo-controlled, phase 2 study

  1. Brian Rini MD1,‡,*,
  2. Cezary Szczylik MD2,
  3. Nizar M. Tannir MD3,
  4. Piotr Koralewski MD4,
  5. Piotr Tomczak MD5,
  6. Andrzej Deptala MD, PhD6,
  7. Luc Y. Dirix MD, PhD7,
  8. Mayer Fishman MD, PhD8,
  9. Rodryg Ramlau MD9,
  10. Alain Ravaud MD, PhD10,
  11. Wojciech Rogowski MD, PhD11,
  12. Karolyn Kracht MS12,
  13. Yu-Nien Sun PhD12,
  14. Michael B. Bass PhD12,
  15. Markus Puhlmann MD12,
  16. Bernard Escudier MD13

Article first published online: 12 JUN 2012

DOI: 10.1002/cncr.27632

Issue

Cancer

Cancer

Volume 118, Issue 24, pages 6152–6161, 15 December 2012

Additional Information

How to Cite

Rini, B., Szczylik, C., Tannir, N. M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L. Y., Fishman, M., Ramlau, R., Ravaud, A., Rogowski, W., Kracht, K., Sun, Y.-N., Bass, M. B., Puhlmann, M. and Escudier, B. (2012), AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney . Cancer, 118: 6152–6161. doi: 10.1002/cncr.27632

Author Information

  1. 1

    The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

  2. 2

    Military Institute of Medicine, Warsaw, Poland

  3. 3

    University of Texas MD Anderson Cancer Center, Houston, Texas

  4. 4

    Szpital Specjalistyczny Ludwika Rydygiera, Kraków, Poland

  5. 5

    University Hospital of Lord's Transfiguration, Poznan, Poland

  6. 6

    Medical University of Warsaw and Central Hospital MSWiA, Warsaw, Poland

  7. 7

    GZA Sint Augustinus, Antwerp, Belgium

  8. 8

    Moffitt Cancer Center, Tampa, Florida

  9. 9

    Poznan University of Medical Sciences, Poznan, Poland

  10. 10

    Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

  11. 11

    ZOZ MSWiA, Gdansk, Poland

  12. 12

    Amgen Incorporated, Thousand Oaks, California

  13. 13

    Institut Gustave Roussy, Villejuif, France

  1. ‡

    Fax: (216) 636-0636

*Cleveland Clinic Taussig Cancer Center, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195

  1. †

    This study is registered at ClinicalTrials.gov, identifier NCT00467025.

  2. ‡

    Fax: (216) 636-0636

Publication History

  1. Issue published online: 3 DEC 2012
  2. Article first published online: 12 JUN 2012
  3. Manuscript Accepted: 12 APR 2012
  4. Manuscript Received: 15 FEB 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (386K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Get PDF (386K)